NCT06830668 is a Phase 4 clinical trial of Regimen：BIC+FTC+TAF in HIV Infection, sponsored by National Center for AIDS/STD Control and Prevention, China CDC.

Who is sponsoring NCT06830668?

NCT06830668 is sponsored by National Center for AIDS/STD Control and Prevention, China CDC.

What drugs are being tested in NCT06830668?

Interventions in NCT06830668: Regimen：BIC+FTC+TAF.

What condition does NCT06830668 study?

NCT06830668 studies HIV Infection, HIV.

Is NCT06830668 still recruiting?

NCT06830668 is currently not yet recruiting. Last updated 17 February 2025.

Last reviewed 2025-02-17 · How we verify

NCT06830668

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Same-Day Restart of B/F/TAF in HIV Patients After NNRTI Discontinuation

Not yet recruiting Phase 4 Last updated 17 February 2025

What this trial tests

Phase 4 trial testing Regimen：BIC+FTC+TAF in HIV Infection in 250 participants. Not yet recruiting.

Timeline

28 February 2025

Primary endpoint
31 December 2026

31 December 2026

Quick facts

Lead sponsor	National Center for AIDS/STD Control and Prevention, China CDC
Phase	Phase 4
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	250
Start date	28 February 2025
Primary completion	31 December 2026
Estimated completion	31 December 2026
Sites	1 location across China

Drugs / interventions tested

Regimen：BIC+FTC+TAF — full drug profile →

Conditions studied

HIV Infection — all drugs for HIV Infection →
HIV — all drugs for HIV →

Sponsor

National Center for AIDS/STD Control and Prevention, China CDC — full company profile →

Who can join

18 and older, any sex, with HIV Infection or HIV. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In China, free first-line ART regimens typically consist of two nucleoside reverse transcriptase inhibitors (NRTIs) and a non-nucleoside reverse transcriptase inhibitor (NNRTI). As of the end of 2022, approximately 1.135 million individuals were receiving ART, achieving a coverage rate of 92.8%, largely due to participation in free treatment programs. However, around 36,000 patients have discontinued treatment, primarily due to side effects associated with Efavirenz (EFV), a common NNRTI. The challenges posed by side effects and resistance profiles of existing NNRTIs highlight the need for effective re-initiation of ART to improve overall treatment coverage. INSTIs, particularly B/F/TAF (Bictegravir/emtricitabine/tenofovir alafenamide), demonstrates effective viral suppression and a higher barrier to resistance than NNRTIs. B/F/TAF has shown efficacy in patients with resistance mutations, making it a strong candidate for same-day ART re-initiation, especially in resource-limited areas where genotypic resistance testing may be unavailable. This study aims to evaluate the feasibility and effectiveness of rapidly restarting B/F/TAF in patients with treatment interruptions from previous NNRTI regimens.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for HIV Infection

Currently open trials in the same condition.

NCT06900829 — #AWARE.HIV Europe: Supporting Healthcare Professionals to Find Undiagnosed HIV in European Hospitals: An Effectiveness-i · NA · recruiting
NCT06908252 — MAPS PrEP Van Study · Phase 4 · recruiting
NCT07042945 — MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003) · Phase 1 · recruiting
NCT06716450 — Multiplo Tp/HIV Self-Test · NA · recruiting
NCT07086989 — Cardiovascular Risk in Children With Chronic Conditions Study · recruiting

Other National Center for AIDS/STD Control and Prevention, China CDC trials

Trials by the same sponsor.

NCT03852849 — Rapid Build of HIV Related Protective Barriers · NA · unknown
NCT01764282 — Promoting Antiretroviral Therapy Among Serodiscordant Couples to Reduce HIV Transmission · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06830668 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Center for AIDS/STD Control and Prevention, China CDC
Last refreshed: 17 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06830668.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing